News

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has ...
BioSpace2d

Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Texas Sues Eli Lilly: 'Big Pharma Compromised Medical Decision-Making'

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Eli Lilly: Bet Against Insiders

Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...